Derivative with cetirizine tetravalent platinum structure and preparation method and application thereof
By inhibiting the histamine signaling axis and PI3K/AKT/mTOR pathway by cetirizine tetravalent platinum compound, the problem of low efficacy and drug resistance of divalent platinum drugs in the treatment of metastatic tumors is solved, and significant anti-tumor is achieved and anti-metastasis effect and reduce toxic side effects.
Patent Information
- Application Number
- CN202410993118.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-07-24
AI Technical Summary
Existing divalent platinum drugs are inefficient in the treatment of metastatic tumors and have dose-dependent toxicity and drug resistance problems, making it difficult to effectively inhibit tumor angiogenesis and immunosuppression microenvironment.
Develop a compound with cetirizine tetravalent platinum structure, which damages DNA through the platinum-main nucleus and inhibits histamine secretion, blocks the HA/HRH1 signal axis, and then inhibits the PI3K/AKT/mTOR pathway, and synergistically exerts anti-tumor proliferation and Anti-metastasis effect.
It significantly improves the therapeutic effect on metastatic malignant tumors, reduces toxic side effects, overcomes the drug resistance of divalent platinum drugs, and activates the anti-tumor immune response, providing a new direction for the development of platinum drugs.
Smart Images

Figure CN119019463A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the fields of pharmacy, chemistry and medical technology, and in particular relates to a derivative having a tetravalent platinum structure of cetirizine, a preparation method thereof and an application thereof in anti-tumor drugs. Background Art
[0002] Despite the continuous progress of surgical, chemotherapy and radiotherapy techniques, malignant tumors remain the main cause of threat to human health. Chemotherapy, as the cornerstone of cancer treatment, is the main method of cancer treatment. Among them, divalent platinum drugs such as cisplatin (CDDP), carboplatin (CBP) and oxaliplatin (OXP) have the advantages of high efficacy and broad anti-tumor spectrum for solid tumors such as testicular cancer, ovarian cancer, bladder cancer, colorectal cancer, lung cancer, head and neck tumors, and occupy an important position in clinical practice. However, with the widespread use of platinum drugs, their efficacy is severely restricted by dose-dependent toxicity and serious acquisition of drug resistance. Metastatic tumors are the key to the death of tumor patients, accounting for about 90% of the deaths of tumor patients, while divalent platinum drugs have a very low efficacy against metastatic cancer. Overcoming the inherent disadvantages of divalent platinum drugs and further improving the anti-metastatic properties of drugs is expected to bring new hope to the development of platinum drugs. Tetravalent platinum complexes are used as prodrugs of divalent platinum drugs. Designing multifunctional tetravalent platinum complexes by adding different functional ligands at the axial position provides an effective strategy for the improvement of platinum drugs. The development of novel multifunctional tetravalent platinum complexes is an effective way to explore new anti-proliferative and anti-metastatic platinum drugs.
[0003] Tumor angiogenesis is the main pathway for delivering nutrients, oxygen, metabolites, and chemical mediators to tumor tissues, and is an important step in tumor development. More importantly, angiogenesis is a key factor in tumor metastasis, providing a metastatic pathway for tumor cells to spread from primary tumors to distant organs. The PI3K / AKT / mTOR pathway plays a key role in a variety of cellular processes, and its abnormal activation in the tumor microenvironment (TME) can promote tumor angiogenesis and promote tumor metastasis. In addition, hypoxic TME is also a key factor in activating PI3K / AKT / mTOR signaling, and accelerates angiogenesis through the hypoxia-inducible factor (HIF) / vascular endothelial growth factor (VEGF) signaling axis. The immunosuppressive TME is a key hallmark of cancer, which has an important impact on tumor growth, metastatic spread, and treatment by promoting tumor cells to escape immune surveillance in the TME. Reversing the "cold tumor" TME to the "hot tumor" TME has become a promising tumor treatment approach, bringing new hope to cancer treatment. As one of the main immune checkpoints (ICPs), the PD-1 / PD-L1 axis promotes cancer immune escape by promoting T cell exhaustion and triggering macrophage polarization to the M2 subtype that favors tumor development. Increasing evidence shows that there is a positive feedback loop between PI3K / AKT / mTOR and PD-L1 in the TME, that is, abnormal activation of PI3K / AKT / mTOR increases the expression of PD-L1 protein, and overexpression of PD-L1 will further stimulate the PI3K / AKT / mTOR pathway. Therefore, regulating PI3K / AKT / mTOR, further inhibiting tumor angiogenesis, and activating anti-tumor immune responses is an effective strategy to prevent tumor spread and metastasis.
[0004] Histamine (HA) is a multifunctional biogenic amine that usually mediates allergic and inflammatory responses by binding to histamine receptors, such as histamine receptor H1 (HRH1). Clinical evidence shows that histamine secretion levels are significantly increased in many tumors, and the HA-HRH1 signaling axis can activate the phosphorylation of PI3K / AKT / mTOR signaling, thereby promoting the development and metastasis of cancer. Histamine is widely involved in stimulating angiogenesis through the HA-HRH1 axis, which is closely related to the COX-2 and HIF / VEGF pathways. In addition, the HA-HRH1 axis is closely related to the M2 polarization of macrophages and T cell dysfunction, and plays an important role in regulating immune responses. Increasing evidence shows that the use of antihistamines during cancer treatment can effectively inhibit tumor angiogenesis, activate antitumor immunity, and further inhibit tumor metastasis. HA-HRH1 has been considered a new target for cancer treatment.
[0005] Cetirizine (CTZ), as a second-generation antihistamine, is a selective inhibitor of HRH1. Studies in recent years have confirmed that CTZ has great potential for development as an anti-tumor drug. Mechanistic detection has found that CTZ is an effective PI3K regulator. More importantly, it has great potential in inhibiting angiogenesis and activating anti-tumor immune responses.
[0006] In view of this, the present invention pioneered the introduction of cetirizine CTZ into the tetravalent platinum system and prepared a novel structure of cetirizine tetravalent platinum target compound. This work belongs to an innovative structural system in the fields of pharmacy, chemistry and medical technology. This type of compound can damage DNA through the platinum nucleus; inhibit histamine (HA) secretion through the cetirizine ligand, block the HA / HRH1 signal axis, inhibit the PI3K / AKT / mTOR pathway, and then inhibit tumor angiogenesis; the two synergistically exert anti-tumor proliferation and anti-metastasis effects. Summary of the invention
[0007] In view of the problems existing in the prior art, the present invention proposes a compound having a tetravalent platinum structure of cetirizine, a preparation method thereof and an application thereof. The anti-tumor proliferation and anti-metastasis effects of the target compound were tested by in vivo and in vitro testing methods, and the anti-tumor mechanism of the drug was studied. The results confirmed that the compound has significant anti-tumor ability, especially has excellent therapeutic effects on metastatic malignant tumors, and is expected to provide new candidate drugs for the clinical treatment of tumors, and provide a new direction for the research and development of new platinum drugs and anti-metastatic malignant tumor drugs.
[0008] The general formula is shown in (Ⅰ):
[0009]
[0010] in, Selected from cisplatin or oxaliplatin; L is hydroxyl or
[0011] Further, the derivative is any one of the following:
[0012]
[0013] The derivatives of the present invention are selected from:
[0014]
[0015] Another object of the present invention is to provide a method for preparing a compound as shown in general formula (I). The synthetic route of the compound is as follows:
[0016] Described synthetic route 1 is as follows:
[0017]
[0018] Compound II and cetirizine CTZ undergo a coupling reaction to obtain an asymmetric monosubstituted cetirizine-modified tetravalent platinum compound Ia; wherein the molar ratio of compound II to cetirizine CTZ is 1:1.0-1.5;
[0019] Described synthetic route 2 is as follows:
[0020]
[0021] Compound II and cetirizine CTZ undergo a coupling reaction to obtain a symmetrical disubstituted cetirizine-modified tetravalent platinum compound Ib; wherein the feed molar ratio of compound II to cetirizine CTZ is 1:2.0-5.0.
[0022] Furthermore, in the synthetic route 1, the preparation steps of the asymmetric monocetirizine tetravalent platinum derivative are:
[0023] Under an inert gas atmosphere, cetirizine CTZ, a condensing agent, and an organic base are dissolved in an anhydrous organic solvent for reaction, compound II is added, and the reaction is carried out in the dark, and then the monocetirizine tetravalent platinum derivative Ia is separated through post-treatment;
[0024] The molar ratio of compound II, cetirizine CTZ, condensing agent and organic base is 1:1.0-1.5:1.0-1.5:1.0-1.5; the feeding relationship between compound II and organic solvent is that 10-100 ml of organic solvent is added for every 1 g of compound II;
[0025] In the second synthetic route, the preparation steps of the symmetrical tetravalent platinum derivative of dicetirizine are as follows:
[0026] Under an inert gas atmosphere, cetirizine CTZ, a condensing agent, and an organic base are dissolved in an anhydrous organic solvent for reaction, compound II is added, and after the reaction is protected from light, a tetravalent platinum derivative of dicetirizine Ib is isolated through post-treatment;
[0027] The molar ratio of compound II, cetirizine CTZ, condensing agent and organic base is 1:2.0-5.0:2.0-5.0:2.0-5.0; the feeding relationship between compound II and organic solvent is that 10-100 ml of organic solvent is added for every 1 g of compound II.
[0028] Furthermore, the inert gas is nitrogen, helium or argon; the condensing agent is TBTU, HATU or EDCI; the organic base is triethylamine, N,N-diisopropylethylamine or 4-dimethylaminopyridine; and the organic solvent is DMF or DMSO.
[0029] The preparation process can be specifically as follows: TBTU and cetirizine CTZ are added to a reaction container, the air in the system is replaced by nitrogen, anhydrous DMSO is added, the reaction is stirred at room temperature, anhydrous triethylamine is added to the reaction system, the reaction is stirred at room temperature, a tetravalent platinum compound II is added to the reaction system, the air in the system is replaced with nitrogen again, and the reaction system is placed at 25 to 120° C. in the dark for reaction for 24 to 72 hours. After the reaction is completed, the solvent is removed under reduced pressure, and column chromatography is performed to obtain an asymmetric monosubstituted cetirizine-modified tetravalent platinum compound Ia or a symmetric disubstituted cetirizine-modified tetravalent platinum compound Ib.
[0030] Further, the compound II is composed of After being oxidized by hydrogen peroxide, the product is prepared. The specific preparation process is as follows:
[0031]
[0032] Divalent platinum compounds The dihydroxy tetravalent platinum compound II is prepared by oxidizing with hydrogen peroxide at 60-70° C. for 1-8 hours.
[0033] In another aspect, the present invention provides a pharmaceutical composition comprising an effective therapeutic amount of a compound represented by the general formula (I) and a pharmaceutically acceptable excipient thereof.
[0034] The pharmaceutically acceptable excipients in the present invention include one or more of carriers, excipients, and diluents; such as binders, lubricants, disintegrants, solubilizers, diluents, stabilizers, suspending agents, pigments, flavoring agents, preservatives, solubilizers, and bases. Pharmaceutically acceptable excipients may be aqueous or non-aqueous. Conventional excipients include colloids, such as gelatin; starches, such as corn starch and potato starch; sugars, such as lactose, glucose, and sucrose; cellulosic materials and mixtures thereof, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate. Pharmaceutically acceptable excipients include, but are not limited to, tragacanth powder, malt, talc, oils (such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, soybean oil, etc.), alcohols (such as propylene glycol, ethanol, glycerol, sorbitol, mannitol, polyethylene glycol, etc.), esters (such as ethyl oleate, ethyl laurate, agar), buffers (such as magnesium hydroxide, aluminum hydroxide, boric acid and sodium borate and phosphate buffer), alginic acid, pyrogen-free water, isotonic saline, Ringer's solution.
[0035] The cetirizine tetravalent platinum compound or pharmaceutical composition of the present invention is in the form of tablets, capsules, aerosols, dispersible tablets, oral liquids, suppositories, pills, large infusions, small injections, freeze-dried powder injections, ointments or liniments, including various sustained-release, controlled-release dosage forms or nano-preparations prepared by conventional methods using currently recognized pharmaceutical common sense.
[0036] The cetirizine tetravalent platinum compound of the present invention can be administered in the form of a unit dose, and the administration route can be enteral and parenteral, such as oral, intramuscular, subcutaneous, nasal, etc.
[0037] The administration route of the tetravalent platinum cetirizine compound of the present invention can be intravenous administration, including intravenous injection, intramuscular injection, intratumor injection, subcutaneous injection and acupoint injection.
[0038] The method of preparing the active ingredient into a drug in the present invention can be prepared by methods known to ordinary technicians in the field, for example: the active ingredient can be diluted with a carrier or encapsulated in a carrier so that it can be quickly released, slowly released or delayed released after administration to a subject.
[0039] Another object of the present invention is to provide the use of the compound or pharmaceutical composition represented by the general formula (I) in the preparation of anti-tumor drugs, specifically in the preparation of anti-tumor proliferation and anti-tumor metastasis drugs.
[0040] The tetravalent platinum derivative of cetirizine described in the present invention can have a good therapeutic effect on metastatic malignant tumors, can effectively inhibit tumor angiogenesis, and effectively activate tumor immune response, and has a good therapeutic effect on metastatic malignant tumors.
[0041] Furthermore, the anti-tumor is anti-lung cancer, anti-resistant lung cancer, anti-liver cancer or anti-breast cancer, etc.; wherein, the anti-tumor proliferation is specifically anti-human lung adenocarcinoma, anti-cisplatin-resistant human lung adenocarcinoma, anti-human liver cancer or anti-mouse breast cancer; the anti-tumor metastasis is anti-mouse breast cancer cells.
[0042] The invention also provides a combined preparation, comprising a compound or pharmaceutical composition as shown in general formula (I) and a combination of paclitaxel, fluorouracil, gemcitabine, vinca alkaloids, and antibodies as anti-tumor drugs.
[0043] The cetirizine derivative tetravalent platinum compound described in the present invention is expected to be used alone or in combination with marketed platinum drugs, paclitaxel drugs, fluorouracil drugs, gemcitabine drugs, vinca alkaloid drugs, antibodies and the like to prepare a combined preparation with anti-tumor activity. The combined preparation can be in the form of tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets, sustained-release tablets, capsules, hard capsules, soft capsules, sustained-release capsules, oral liquids, mixtures, lozenges, granules, electuary preparations, pills, powders, pastes, suspensions, solutions, injections, powder injections, freeze-dried powder injections, suppositories, liniments, ointments, plasters, creams, sprays, aerosols, drops, patches and the like.
[0044] Compared with the prior art, the compound having the structure of tetravalent platinum of cetirizine described in the present invention has the following advantages:
[0045] (1) Conventional chemotherapy has a weak effect on metastatic tumors, which is the main reason for the failure of chemotherapy. The present invention successfully synthesizes a series of novel cetirizine tetravalent platinum compounds by combining the cetirizine molecule with the tetravalent platinum system. These compounds have shown significant anti-tumor and anti-cancer effects in anti-tumor activity experiments, especially for metastatic malignant tumors, and have great development prospects for development into anti-tumor metastasis drugs.
[0046] (2) Angiogenesis is a key step in promoting tumor development and metastasis. The introduction of the cetirizine group in the target compound inhibits the secretion of histamine (HA), blocks the HA / HRH1 signaling axis, inhibits the PI3K / AKT / mTOR pathway, inhibits chronic inflammation, hypoxia, and immunosuppressive tumor microenvironment, and thus inhibits tumor angiogenesis; platinum-based nuclei induce DNA damage. The two work together to exert effective anti-tumor proliferation and anti-metastasis effects.
[0047] (3) Strong toxicity and side effects are one of the main reasons for the failure of platinum-based chemotherapy. While the tetravalent platinum compound cetirizine exerts excellent anti-tumor activity, its toxicity and side effects are significantly lower than those of cisplatin, and it can effectively overcome clinical bivalent platinum drug resistance, showing significant therapeutic advantages.
[0048] (5) The structural innovation of the compound of general formula I described in the present invention is expected to obtain a variety of lead molecules that are effective against tumors, opening up a new path for the development of platinum compounds. This type of original innovative drug research has important theoretical value and practical significance for national economic and social development and people's health. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 . Drug accumulation in 4T1 cells in vitro. 4T1 cells were cultured with complexes 1-4 (5 μM), CDDP (5 μM) and the mixture CDDP-CTZ (5 μM / 10 μM) for 24 hours, and the Pt element was detected by AAS method, and then the drug uptake level was detected. ***P<0.001
[0050] Figure 2 .Subdistribution of drugs in 4T1 cells in vitro. 4T1 cells were cultured with complex 1 (5μM), CDDP (5μM) and the mixture CDDP-CTZ (5μM / 10μM) for 24 hours. The cell nucleus, cytoplasm and cell membrane were separated, and the Pt element was detected by AAS method, and then the cellular subdistribution of drugs was detected. ***P<0.001
[0051] Figure 3Western blot analysis of γ-H2AX and P53 expression. 4T1 cells were incubated with cetirizine tetravalent platinum complex 1 (5 μM), CDDP (5 μM) and a mixture of CDDP-CTZ (5 μM / 10 μM) for 24 hours.
[0052] (a) Western blot results; (b) Relative gray intensity analysis. Relative gray = (gray of specific protein) / (gray of GAPDH). ***P<0.001.
[0053] Figure 4 .Drug-induced cell apoptosis activity test. 4T1 cells were treated with drugs (5μM) for 24h, stained with Annexin V-FITC / PI, and measured by flow cytometry. (a) Blank; (b) CDDP (5μM); (c) CDDP-CTZ (5μM / 10μM); (d) Cetirizine tetravalent platinum complex 1 (5μM).
[0054] Figure 5 Drug-induced mitochondrial membrane potential (ΔΨm) impairment activity test. 4T1 cells were treated with platinum complexes at 37°C for 24 h, stained with JC-1, and measured by flow cytometry. (a) Blank; (b) CDDP (5 μM); (c) CDDP / CTZ (5 μM / 10 μM); (d) Cetirizine tetravalent platinum complex 1 (5 μM).
[0055] Figure 6 .Drug-induced ROS generation activity test. DCFH-DA staining was used to detect ROS generated by 4T1 cells after treatment with CDDP (10 μM), OXP (10 μM) and cetirizine tetravalent platinum complex 1 (10 μM) for 24 hours. (a) Representative micrographs; (b) Statistical analysis of fluorescence intensity by flow cytometry. ***P<0.001.
[0056] Figure 7 .Western blot analysis of Bcl-2, Bax, caspase3 and c-caspase3 expression. 4T1 cells were incubated with cetirizine tetravalent platinum complex 1 (5μM), CDDP (5μM) and CDDP-CTZ mixture (5μM / 10μM) for 24 hours. (a) Western blot experimental results; (b) relative gray intensity analysis. ***P<0.001.
[0057] Figure 8. Detection of HRH1 by Elisa. (a) HRH1 in the serum of mice treated with Blank, CDDP, CDDP-CTZ and cetirizine tetravalent platinum complex 1; (b) HRH1 in the tumors of mice treated with Blank, CDDP, CDDP-CTZ and cetirizine tetravalent platinum complex 1. Both serum and tumor were from in vivo anti-tumor experiments. Data were calculated based on three parallel experiments. ***P<0.001.
[0058] Fig. 9 . HA was detected by Elisa. (a) HA in the serum of mice treated with Blank, CDDP, CDDP-CTZ and cetirizine tetravalent platinum complex 1; (b) HA in the tumors of mice treated with Blank, CDDP, CDDP-CTZ and cetirizine tetravalent platinum complex 1. Serum and tumors were obtained from in vivo antitumor experiments. Data were calculated based on three parallel experiments. ***P<0.001.
[0059] Fig.10 Western blot analysis of PI3K, p-PI3K, AKT, p-AKT, mTOR, and p-mTOR expression. 4T1 cells were incubated with cetirizine tetravalent platinum complex 1 (5 μM), CDDP (5 μM), and CDDP-CTZ mixture (5 μM / 10 μM) for 24 hours. (a) Western blot experimental results; (b) relative gray intensity analysis. ***P<0.001.
[0060] Fig.11 .In vitro HUVEC cells were used to detect the anti-angiogenic properties of cetirizine tetravalent platinum complex 1. HUVEC cells were treated with CDDP (5μM), mixture CDDP-CTZ (5μM / 10μM), mixture CDDP-CTZ-HA (5μM / 10μM / 10μM), cetirizine tetravalent platinum complex 1 (5μM) and mixture 1-HA (5μM / 10μM) for 24 hours. (a) Representative images; (b) Relative angiogenesis of each group compared with the blank control. Data are based on three parallel experiments. ***P<0.001.
[0061] Fig.12 Cetirizine tetravalent platinum complex 1 inhibits angiogenesis by inhibiting tumor inflammation and hypoxic microenvironment. (a, b) CD34 in tumor tissues in in vivo anti-tumor experiments +Immunohistochemical staining of microvessels; (c) Elisa to detect the relative levels of inflammatory cytokines IL-6 and TNF-α in serum. Serum was obtained from in vivo anti-tumor experiments; (d, e) Western blot analysis of COX-2, MMP9, HIF-1α and VEGFA expression; 4T1 cells were incubated with cetirizine tetravalent platinum complex 1 (5μM), CDDP (5μM) and CDDP-CTZ mixture (5μM / 10μM) for 24 hours, followed by Western blot analysis. **P<0.01, ***P<0.001.
[0062] Fig.13 Immunohistochemical staining of HIF-1α, VEGFA, and MMP9 in tumor tissues in vivo. Tissues were obtained from in vivo anti-tumor experiments. (a) Representative photos; (b) Quantitative data. *** P<0.001.
[0063] Fig.14 Effect of histamine on angiogenesis. 4T1 cells were treated with cetirizine tetravalent platinum complex 1 (5μM), mixture CDDP-CTZ (5μM / 10μM), mixture 1-HA (5μM / 10μM), and mixture CDDP-CTZ (5μM / 10μM / 10μM) for 24 hours. (a) Western blot analysis of COX-2, HIF-1α, and VEGFA levels; (b) relative gray intensity analysis. ***P<0.001.
[0064] Fig.15 .Effect of Cetirizine Tetravalent Platinum Complex 1 on Tumor Immunity. (a, b) Western blot analysis of PD-L1 expression in 4T1 cells treated with Cetirizine Tetravalent Platinum Complex 1 (5 μM), CDDP (5 μM) and mixture CDDP-CTZ (5 μM / 10 μM) for 24 hours. (c, d) Expression of PD-L1 and CD3 in tumor tissues in in vivo anti-tumor experiments + and CD8 + T cells and CD86 + -M1 and CD206 + -Immunohistochemical staining of M2 macrophages. ***P<0.001.
[0065] Fig.16.In vivo antitumor activity of cetirizine tetravalent platinum complex 1, CDDP and CDDP-CTZ against female BALB / c mice (n=6) bearing 4T1 tumors. ***P<0.001. (a) Schematic diagram of experimental design; (b) Functional relationship between tumor growth and time; (c) Tumor weight of mice in each group at the end of the experiment; TGI of the tested drug compared with the blank group was indicated by [TGI=(1-tumor weight of drug-treated group / tumor weight of blank group)×100%]; (d) Platinum accumulation in tumor tissues was detected by AAS method; (e) Tumor images after mice were sacrificed; (f) Relative weight of mice during treatment; (g) H&E staining images of tumors.
[0066] Fig.17 .Organ index of BALB / c mice in the blank group, cetirizine tetravalent platinum complex 1 group, CDDP group and CDDP-CTZ treatment group (n=6). Tissues were obtained from in vivo anti-tumor experiments. (a) Heart; (b) Liver; (c) Spleen; (d) Lung; (e) Kidney; Organ index = organ weight / body weight × 100%. ***P<0.001; ns: no significant difference.
[0067] Fig.18 .H&E staining of liver, spleen and kidney tissues of mice in the control, CDDP, CDDP-CTZ and cetirizine tetravalent platinum complex 1 treatment groups. Tissues were obtained from in vivo antitumor experiments.
[0068] Fig.19 .In vitro Transwell assay was used to evaluate the migration inhibition properties of cetirizine tetravalent platinum complex 1 (5μM), CDDP (5μM) and CDDP-CTZ (5μM / 10μM) on 4T1 cells. 4T1 cells were observed after 24 hours of treatment with platinum drugs, and untreated cells were set as blank. (a) Representative images; (b) Relative migration rate analysis. ***P<0.001.
[0069] Fig. 20 .The inhibitory effects of cetirizine tetravalent platinum complex 1 (5 μM), CDDP (5 μM) and CDDP-CTZ (5 μM / 10 μM) on 4T1 cell migration in vitro were detected by scratch assay. The extent of scratch healing was observed at 0, 12 and 24 hours. (a) Representative images; (b) Scratch healing analysis. *P<0.05, **P<0.01, ***P<0.001, ns: no significant difference.
[0070] Fig.21Inhibitory effects of cetirizine tetravalent platinum complex 1 and CDDP on the in vivo 4T1 tumor lung metastasis model (n=5). ***P<0.001. (a) Schematic diagram of the experimental design; (b) Representative photos of the front and back of the lungs of each group at the end of the experiment; (c) Statistics of lung nodules in each group. The inhibition rate is given above the column; (d) H&E staining of lung metastatic nodules, with nodules indicated by arrows. DETAILED DESCRIPTION
[0071] The technical scheme of the present invention is further described in conjunction with specific embodiments, but the implementation is intended to explain the present invention and cannot be understood as limiting the present invention. If no specific technology or conditions are specified in the embodiments, the technology or conditions described in the literature in the field or the product instructions shall be followed. Unless otherwise defined, the technical terms used in the following embodiments have the same meanings as those generally understood by technicians in the field to which the present invention belongs; the test reagents used, unless otherwise specified, are conventional biochemical reagents; the experimental methods, unless otherwise specified, are conventional methods.
[0072] In order to make the objectives, technical solutions and advantages of the present invention more clear, representative embodiments of the present invention are described in detail below, but are not limited thereto.
[0073] Example 1.
[0074] 1. Preparation of tetravalent platinum shown in structural formula II
[0075] 1. Synthesis of dihydroxycisplatin tetravalent platinum IIa
[0076]
[0077] In a 250mL round-bottom flask, add 1.0g cisplatin and 30mL distilled water. Under stirring, slowly add 50mL of 30% hydrogen peroxide to the reaction system. Raise the temperature to 60°C and continue stirring to react for 4 hours. After the reaction is completed, crystallize at 4°C for 12 hours, filter and separate to obtain a yellow solid crude product, and recrystallize from pure water to obtain IIa as 0.78g of yellow crystals with a yield of 70%.
[0078] 2. Synthesis of dihydroxyoxaliplatin tetravalent platinum IIb
[0079]
[0080] In a 250mL round-bottom flask, add 1.0g of oxaliplatin and 30mL of distilled water. Under stirring, slowly add 50mL of 30% hydrogen peroxide to the reaction system. Raise the temperature to 60°C and continue stirring to react for 4 hours. After the reaction is completed, crystallize at 4°C for 12 hours, filter and separate to obtain a white solid crude product, and recrystallize from pure water to obtain IIb as 0.68g of white crystals with a yield of 63%.
[0081] 2. Preparation of Cetirizine Tetravalent Platinum Shown in Structural Formula I
[0082] 1. Preparation of symmetrical dicetirizine tetravalent platinum derivative 1.
[0083]
[0084] CTZ (350 mg, 0.90 mmol) and HATU (342 mg, 0.90 mmol) were added to 5 mL of dry DMSO, and the mixture was stirred at room temperature for 15 min. Then, triethylamine (125 μL, 0.90 mmol) was added and stirring was continued for 15 min. Subsequently, IIa (100 mg, 0.30 mmol) was added, nitrogen was replaced, and the reaction was vigorously stirred at 55 ° C in the dark for 48 hours. After the reaction was completed, the solvent was evaporated and the crude product was purified by silica gel column chromatography to obtain a white solid complex 1 (83.7 mg, 22.3%). The purity was 97.0% as determined by HPLC (75% methanol / 25% water).
[0085] 1 H NMR (500MHz, DMSO-d6) δ7.47–7.44(m,4H),7.42–7.40(m,4H),7.37(d,J=8.5Hz,4H),7.31(t,J=7.6Hz,4H),7.21(t,J= 7.3Hz,2H),4.80(br,6H,NH3),4.41(s,2H),3.89(s,4H),3.65(t,J=5.4Hz,4H),3.01–2.67(m,16H),2.58–2.52(m,4H). 13 C NMR (126MHz, DMSO-d6) δ172.0,141.8,141.4,132.2,129.8,129.3,129.2,128.0,127.8,73.1,67.8,65.2,55.2,51.8,48.3.MS-ESI:calcd for[M] + :1076(M=C 42 H 54 Cl4N6O6Pt),found:1076.HRMS:calcd for[M] + :1074.2585(M=C 42 H 54 Cl4N6O6Pt), found:1074.2579.
[0086] 2. Preparation of symmetrical dicetirizine tetravalent platinum derivative 2.
[0087]
[0088] CTZ (272 mg, 0.7 mmol) and TBTU (224 mg, 0.7 mmol) were added to 5 mL DMF, and the mixture was stirred at room temperature for 15 min. Then, triethylamine (97 μL. 0.7 mmol) was added, and the mixture was stirred for 15 min. Compound IIb (100 mg, 0.23 mmol) was subsequently added, nitrogen was replaced, and the reaction was stirred vigorously at 55° C. in the dark for 48 hours. After completion, the solvent was evaporated, and the crude product was purified by silica gel column chromatography to obtain a white solid complex 2 (111.6 mg, 27.6%). The purity was 95.4% as determined by HPLC (75% methanol / 25% water).
[0089] 1 H NMR(500MHz,DMSO-d6)δ8.48–8.30(m,2H,NH2),8.14–7.96(m,2H,NH2),7.49–7.42(m, 4H),7.41–7.35(m,8H),7.33–7.27(m,4H),7.24–7.19(m,2H),4.39(s,2H),4.04(s,4H) ,3.64–3.56(m,4H),3.12–3.06(m,2H),2.87–2.72(m,8H),2.60–2.54(m,2H),2.48–2. 36(m,8H),2.10–2.04(m,1H),1.52–1.40(m,3H),1.28–1.17(m,4H),1.14–1.06(m,2H). 13 C NMR(126MHz,DMSO-d6)δ177.8,163.9,142.4,142.0,131.9,129.9,129.1,129.0, 128.0,127.6,74.0,68.5,61.4,53.0,50.4,46.1,31.3,24.0,9.1.MS-ESI:calcd for[M] + :1173(M=C 50 H 62 Cl2N6O 10 Pt),found:1173.HRMS:calcd for[M+H] + :1172.3630(M=C 50 H 62 Cl2N6O 10 Pt),found:1172.3654.
[0090] 3. Preparation of asymmetric monocetirizine tetravalent platinum derivative 3.
[0091]
[0092] CTZ (117 mg, 0.3 mmol) and HATU (114 mg, 0.30 mmol) were added to 5 mL DMSO, and the mixture was stirred at room temperature for 15 min. Then, triethylamine (42 μL, 0.30 mmol) was added, and the mixture was stirred for 15 min. Compound IIa (100 mg, 0.30 mmol) was then added, nitrogen was replaced, and the reaction was stirred vigorously at 55 ° C in the dark for 48 hours. After the reaction was completed, the solvent was evaporated and the crude product was purified by silica gel column chromatography to obtain a yellow solid complex 3 (51.4 mg, 21.5%). The purity was 98.0% as determined by HPLC (75% methanol / 25% water).
[0093] 1 H NMR(500MHz,DMSO-d6)δ7.46(d,J=8.2Hz,2H),7.44–7.36(m,4H),7.32(t,J=7.5Hz,2H),7.23(d ,J=7.4Hz,1H),4.47(s,1H),3.97(s,2H),3.73(t,J=5.1Hz,2H),3.14–2.87(m,8H),2.54(s,2H). 13 C NMR (126MHz, DMSO) δ172.7,142.0,141.7,132.0,129.8,129.2,129.1,128.0,127.8,73.5,68.6,66.1,55.8,52.1,49.2.MS-ESI:calcd for[M+2HCl+H] + :779(M=C 21 H 31 Cl3N4O4Pt),found:779.
[0094] 4. Preparation of asymmetric monocetirizine tetravalent platinum derivative 4.
[0095]
[0096] CTZ (89 mg, 0.23 mmol) and TBTU (74 mg, 0.23 mmol) were added to 5 mL of DMF, and the mixture was stirred at room temperature for 15 min. Triethylamine (32 μL. 0.23 mmol) was then added, and the mixture was stirred for another 15 min. Compound IIb (100 mg, 0.23 mmol) was subsequently added, the nitrogen was replaced, and the reaction was stirred vigorously at 55° C. in the dark for 48 hours. After the reaction was completed, the solvent was evaporated, and the crude product was purified by silica gel column chromatography to obtain a white solid complex 4 (44.2 mg, 21.6%). The purity was 97.9% as determined by HPLC (75% methanol / 25% water).
[0097] 1 H NMR (500MHz, DMSO-d6) δ7.44(d,J=8.2Hz,2H),7.39(d,J=7.7Hz,2H),7.35(d,J=8.3Hz,2H),7.29(t,J=7.6Hz,2H),7.20(d,J=7.3Hz,1H),4.34(s, 1H),4.02(s,2H),3.56(s,2H),2.80–2.56(m,6H),2.38–2.34(m,4H),2.1 4–2.08(m,2H),1.48–1.40(m,2H),1.25–1.21(m,2H),1.18–0.78(m,2H). 13 CNMR(126MHz,MeOD)δ186.7,166.3,141.3,140.8,132.6,129.2,128.6,128.5,1 27.6,127.3,73.8,68.0,64.8,61.2,56.2,52.5,52.5,34.0,7.9.MS-ESI:calcd for[M+H] + :803(M=C 29 H 39 ClN4O8Pt),found:803.HRMS:calcd for[M+H] + :802.2182(M=C 29 H 39 ClN4O8Pt), found:802.2190.
[0098] 3. Experimental Test
[0099] In order to better understand the essence of the present invention, the pharmacological test results of the inhibitory effect of the compounds on tumors in vivo and in vitro experiments are used below to illustrate the potential use of these compounds in the pharmaceutical field. The pharmacological experiments provide partial activity data of some compounds. It must be noted that the pharmacological experiments of the present invention are used to illustrate the present invention rather than to limit the present invention. Simple improvements made to the present invention according to the essence of the present invention all belong to the protection scope of the present invention.
[0100] 1. In vitro antitumor activity assay
[0101] In this experiment, the MTT method was used to determine the cell survival rate. The half-inhibitory concentration (IC 50 ) values were used to evaluate the in vitro anticancer activity of the complexes.
[0102] Inoculate 100 μL of tumor cells in the logarithmic growth phase into a 96-well plate with a cell density of 5000-8000 / well, and leave the last column as a zero well. Place in a 37°C cell culture incubator for 12 hours, then add 100 μL of compound culture medium solution with gradient concentrations to the 96-well plate, and continue to culture in a 37°C cell culture incubator for 48 hours. Add 20 μL of 5 mg / mL MTT solution to each well of the 96-well plate, take out after 4 hours of incubation, remove the culture medium, add 150 μL of DMSO, and shake in a 37°C shaker in the dark for 20 minutes. Use an enzyme-linked immunosorbent assay reader to measure the absorbance OD value of each well at 490 nm and calculate its IC 50 Each set of experiments was repeated at least three times.
[0103] The cancer cell lines used in this experiment include: human lung adenocarcinoma cell line A549, cisplatin-resistant lung adenocarcinoma cell line A549R, mouse breast cancer cell line 4T1, human liver cancer cell line HepG2, and human normal liver cell line LO-2.
[0104] The reference drugs used in this experiment include: cetirizine CTZ, cisplatin CDDP, oxaliplatin OXP, a mixture of cisplatin and CTZ CDDP-CTZ, and sitraplatin STP.
[0105] Discussion of Antitumor Activity:
[0106] Table 1 In vitro antitumor activity of CTZ tetravalent platinum compounds.
[0107]
[0108]
[0109] Table 1 a RF: resistance factor, RF = IC 50 (A549R) / IC 50 (A549); bSI: Selectivity index, SI = IC 50 (LO2) / IC 50 (HepG2); c ND: not tested or not calculated; d CDDP-CTZ: a mixture of cisplatin and CTZ with a molar ratio of 1:2.
[0110] The results are shown in Table 1: The ligands in the CTZ tetravalent platinum complexes significantly affect drug uptake, which further affects the anti-tumor efficacy. Compared with the single CTZ tetravalent platinum complexes 3 and 4, the complexes 1 and 2 with dual CTZ ligands have higher drug accumulation in tumor cells (P<0.001)( Figure 1 ), and the anti-tumor performance is better. In addition, the platinum core plays a key role in affecting the anti-tumor efficacy of cetirizine tetravalent platinum complexes. The CDDP-based complexes 1 and 3 are more active than the corresponding OXP-derived complexes 2 and 4. In particular, cetirizine tetravalent platinum complex 1 (i.e., symmetrical dual cetirizine tetravalent platinum derivative 1) has the strongest anti-tumor activity, with an IC 50 The value is lower than 4.61 μM, which is stronger than cisplatin, 1.63-7.13 times the activity of the reference drug CDDP, and significantly stronger than OXP and the tetravalent platinum drug STP. It is worth noting that the ligand CTZ has a very low killing effect on tumor cells, and the anti-tumor ability of the mixture of CDDP and CTZ (CDDP-CTZ) is not significantly enhanced compared with free CDDP. These facts show that fusing CTZ with the tetravalent platinum mother core to construct a cetirizine tetravalent platinum compound is a key step in improving anti-tumor performance.
[0111] Drug resistance is a major obstacle to the clinical effectiveness of platinum drugs. To evaluate the ability of CTZ tetravalent platinum complexes to overcome drug resistance, the resistance factor (RF) (IC 50 Value and A549 IC 50 The results showed that cetirizine tetravalent platinum complex 1 effectively overcame the drug resistance of CDDP, with an RF value of 0.72, which was significantly lower than that of CDDP (RF = 3.86), while the CDDP-CTZ mixture had a weaker effect on it (RF = 3.19). Then, we calculated the selectivity index (SI) of the drug to determine the in vitro toxicity of CTZ tetravalent platinum complex (IC 50 Value and LO2 IC 50 The results showed that cetirizine tetravalent platinum complex 1 could reduce the toxicity to normal cells, and its SI value was 2.77, which was higher than CDDP (SI = 0.81), OXP (SI = 0.60) and JM216 (SI = 0.90) and CDDP-CTZ mixture (SI = 0.98).
[0112] Therefore, the symmetrically disubstituted cetirizine tetravalent platinum derivative 1 exhibited satisfactory antitumor activity in vitro and had great potential in overcoming CDDP resistance and reducing toxicity. Therefore, the complex was screened out and further activity and mechanism studies were conducted as an antiproliferative and anti-metastatic drug candidate.
[0113] 2. DNA damage mechanism
[0114] DNA damage is the main anti-tumor mechanism of platinum drugs. We used Western Blot to detect the expression of DNA damage marker proteins. AAS was used to detect the Pt element and the distribution of drugs in cells was detected.
[0115] 4T1 cells in logarithmic growth phase were placed in 6-well plates (10 6 / well), cultured in a 37°C, 5% carbon dioxide incubator for about 12 hours, treated with drugs, and continued to culture for 24 hours. Digested with EDTA-free trypsin and collected the cells. Washed the cells twice with PBS, nitrolyzed with concentrated nitric acid, and the platinum content in the cells was detected by atomic absorption spectrometry, thereby measuring the drug uptake in tumor cells. The drug-treated cells were obtained in the same way, and the cell nucleus, cytoplasm, and cell membrane were separated using a kit, nitrolyzed with concentrated nitric acid, and the platinum content in each part was detected by atomic absorption spectrometry, thereby measuring the sub-distribution of the drug in tumor cells.
[0116] The cells were collected and treated with the above method, proteins were extracted, and electrophoretic protein separation was performed using SDS-Page, and the membrane was transferred to a PVDF membrane. After blocking in 5% skim milk for 1 hour, the membrane was incubated with the primary antibody at 4°C overnight, incubated with the secondary antibody for 1 hour, and then developed with ECL chemiluminescent colorimetric solution, and the membrane was imaged using the Tanon 46000SF scanning system. This patent detected the expression of DNA damage marker proteins γ-H2AX and P53 by Western Blot, and examined their ability to damage DNA.
[0117] The accumulation of tetravalent platinum complexes in the nucleus is considered to be a key step in exerting their DNA damaging effects. Here, we used AAS detection to study the distribution of cetirizine tetravalent platinum complex 1 in tumor cells. Figure 1 The results in the study showed that the intracellular uptake level of cetirizine tetravalent platinum complex 1 was higher than that of CDDP and CDDP-CTZ. Figure 2 It was confirmed that its accumulation in nuclear DNA was also significantly higher than that of CDDP and CDDP-CTZ. This indicates that CTZ tetravalent platinum complex 1 can effectively enter tumor cells, then accumulate in the nucleus and affect its anti-tumor activity, which may be one of the reasons why the MTT anti-tumor activity of cetirizine tetravalent platinum complex 1 is stronger than that of CDDP and CDDP-CTZ.
[0118] To further prove that cetirizine tetravalent platinum complex 1 can cause DNA damage, we used Western Blot to test the expression of DNA damage indicator proteins γ-H2AX and P53. Figure 3 As shown in the figure, the expression of γ-H2AX and P53 in 4T1 cells was significantly increased after treatment with cetirizine tetravalent platinum complex 1 (P<0.001). These results verified the strong DNA damage ability of CTZ tetravalent platinum complex 1.
[0119] 3. Induce mitochondria-mediated apoptosis.
[0120] To further verify the mechanism of cell death induced by CTZ tetravalent platinum compounds, we used AnnexinV-FITC / PI double staining to detect the characteristics of drug-induced cell apoptosis. The process of cell apoptosis often involves mitochondria and is accompanied by the collapse of mitochondrial membrane potential and the generation of ROS. Therefore, we used JC-1 staining to detect changes in mitochondrial membrane potential; DCFH-DA staining to detect intracellular ROS levels; and Western Blot to detect the effects of drugs on apoptotic proteins. The mechanism of CTZ tetravalent platinum compounds inducing apoptosis of tumor cells was explored.
[0121] Take 4T1 cells in logarithmic growth phase in good condition and place them in 6-well plates (10 6 / well), cultured in a 37°C, 5% carbon dioxide incubator for about 12 hours, treated with drugs, and continued to culture for 24 hours. Digest the cells with EDTA-free trypsin, collect, and divide into 3 parts. In the first part, wash the cells twice with PBS, add 5μL of Annexin V-FITC stain and 5μL of PI stain respectively, mix well, react at room temperature in the dark for 5-15min, and test the samples with flow cytometer within 1 hour. In the second part, stain with DCFH-DA to detect the production of ROS in the cells, and detect with a fluorescent inverted microscope and flow cytometer. The third part was stained with JC-1 and detected by flow cytometer to examine the changes in mitochondrial membrane potential.
[0122] like Figure 4 As shown in Figure 2, cetirizine tetravalent platinum complex 1 can significantly induce apoptosis of 4T1 tumor cells (29.8%), which is relatively higher than CDDP (23.8%) and CDDP-CTZ mixture (19.6%). This trend is consistent with IC 50 The values are consistent. Mitochondrial-dependent apoptosis is one of the most important pathways of cell apoptosis. Mitochondrial membrane potential (ΔΨ m ) collapse and ROS generation are the characteristics of mitochondrial damage. The results showed that cetirizine tetravalent platinum complex 1 induced ΔΨ m The obvious collapse of Figure 5 ), and then the production of ROS was significantly increased compared with the blank group (P<0.001)( Figure 6 ). Obviously, severe mitochondrial damage was induced during complex 1-induced apoptosis.
[0123] The Bcl-2 signaling pathway is a key pathway that controls mitochondrial apoptosis. This patent uses Western Blot to determine the expression of Bcl-2 pathway proteins ( Figure 7 ). Cetirizine tetravalent platinum complex 1 inhibited the anti-apoptotic protein Bcl-2 (P < 0.001), while the expression of pro-apoptotic protein Bax and apoptotic protein c-caspase3 / caspase3 was significantly upregulated (P < 0.001). These facts indicate that CTZ tetravalent platinum complex can effectively promote tumor cell apoptosis through the mitochondria-mediated Bcl-2 / Bax / caspase3 pathway.
[0124] 4. Inhibit HA-HRH1 signaling axis.
[0125] High expression of histamine in tumor tissue accelerates cancer-related biological processes by activating the HA-HRH1 axis. Cetirizine CTZ, as a second-generation antihistamine, can selectively inhibit the HA-HRH1 axis, thereby exerting important effects on immunosuppression, angiogenesis, and tumor metastasis. CTZ tetravalent platinum complex is expected to inhibit HA secretion and HRH1 activity after CTZ is released by reduction. We used Elisa assay to understand the effect of cetirizine tetravalent platinum complex 1 on the HA-HRH1 signaling axis.
[0126] The in vivo detection of histamine levels and HRH1 expression in serum and tumor tissues was performed using Elisa kits (Jiangsu Enzyme-Free Biotechnology Co., Ltd.). Serum and tumor tissues were obtained from the in vivo antitumor activity experiment. The experiment was performed according to the manufacturer's protocol. The results were calculated based on three parallel experiments.
[0127] Figure 8 The results in the study showed that HRH1 in serum and tumor tissues of the group treated with cetirizine tetravalent platinum complex 1 was significantly inhibited (P < 0.001), and its inhibitory effect was better than that of the CDDP-CTZ mixture (P < 0.01), while the effect of CDDP on HRH1 activity was negligible. Subsequently, the secretion of HA in serum and tumor tissues of the group treated with cetirizine tetravalent platinum complex 1 was also reduced (P < 0.001), which was lower than that of the CDDP-CTZ mixture (P < 0.001) ( Fig. 9 ). It can be seen that cetirizine tetravalent platinum complex 1 can exert anti-tumor activity in vivo by inhibiting the HA-HRH1 signaling axis.
[0128] 5. Inhibit PI3K / AKT / mTOR signaling pathway
[0129] The PI3K / AKT / mTOR pathway is a key convergence point of multiple signal cascade reactions and plays an important role in promoting angiogenesis and inducing immunosuppression in tumor tissues. It is reported that the overactivated HA-HRH1 signaling axis in tumors can effectively activate the PI3K / AKT / mTOR pathway, and CTZ is an inhibitor of the HA-HRH1 and PI3K pathways. The present invention evaluates the inhibitory effect of cetirizine tetravalent platinum complex 1 on PI3K / AKT / mTOR signal transduction by Western blot analysis.
[0130] Fig.10 Blots in the Figure 2 showed that p-PI3K, p-AKT, and p-mTOR proteins were simultaneously downregulated in tumor cells treated with cetirizine tetravalent platinum complex 1, and the ratios of p-PI3K / PI3K, p-AKT / AKT, and p-mTOR / mTOR decreased significantly, which were significantly lower than those in the blank group (P < 0.001). It is worth noting that the CDDP-CTZ mixture also had a significant inhibitory effect on p-PI3K / PI3K, p-AKT / AKT, and p-mTOR / mTOR (P < 0.001), while CDDP had a smaller effect on these proteins. Therefore, we have reason to speculate that the CTZ ligand is involved in the inhibition of PI3K / AKT / mTOR, and the inhibitory effect of CTZ tetravalent platinum complex 1 is mainly attributed to the CTZ ligand. The inhibitory mechanism of cetirizine tetravalent platinum complex 1 on PI3K / AKT / mTOR signaling further affects tumor angiogenesis and immune regulation.
[0131] 6. Inhibit angiogenesis by inhibiting tumor inflammation and hypoxia.
[0132] Inhibition of tumor angiogenesis is considered to be a key therapeutic target for inhibiting tumor proliferation and metastasis. Cetirizine tetravalent platinum complex 1 has the property of inhibiting HA, so it is expected to inhibit angiogenesis. To further verify this hypothesis, the researchers used HUVEC cells to evaluate the anti-angiogenic properties of cetirizine tetravalent platinum complex 1 in vitro, and detected the in vivo anti-angiogenic activity of cetirizine tetravalent platinum complex 1 in tumor tissues by immunohistochemical staining using CD34 as an angiogenesis marker. Fig.11 The results showed that cetirizine tetravalent platinum complex 1 could effectively inhibit angiogenesis in vitro, which was more significant than the blank group and CDDP group (P<0.001). Fig.12 As shown in ab, CD34 +Microvessels were also significantly inhibited, indicating that angiogenesis in tumors treated with cetirizine platinum complex 1 was significantly reduced compared with the control and CDDP groups, and even lower than the CDDP-CPZ combination group. These findings suggest that cetirizine platinum complex 1 can effectively inhibit angiogenesis both in vitro and in vivo.
[0133] Angiogenesis is closely related to TME. HA in TME can enhance inflammation and hypoxia conditions in tumors, which plays a vital role in promoting angiogenesis. To investigate the relationship between angiogenesis inhibition and inflammatory and hypoxic TME, the researchers used Western blot analysis and immunohistochemical staining to evaluate the expression of inflammation-related COX-2 and MMP-9, as well as the expression of the hypoxia-related HIF-1α / VEGFA axis; Elisa was used to detect inflammatory cytokines TNF-α and IL-6 in TME.
[0134] The study found that cetirizine tetravalent platinum complex 1 effectively inhibited the inflammatory response in the TME compared with the control group, as evidenced by the downregulation of COX-2 and MMP-9 in tumor cells (P<0.001)( Fig.12 de). At the same time, after treatment with cetirizine tetravalent platinum complex 1, the levels of TNF-α and IL-6 in TME were significantly reduced (P<0.001) ( Fig.12 c). In addition, compared with the control group, cetirizine tetravalent platinum complex 1 reversed hypoxia by reducing the expression of HIF-1α (P<0.01) and VEGFA (P<0.001). These results were further demonstrated in the results of immunohistochemical staining, where the accumulation of MMP9, HIF-1α, and VEGFA in tumor tissues was also significantly reduced compared with the blank group and CDDP group (P<0.001)( Fig.13 ). These results suggest that cetirizine platinum complex 1 effectively inhibits angiogenesis by targeting inflammation and hypoxia in the TME.
[0135] To further investigate whether the inhibitory effects of cetirizine platinum complex 1 on inflammation and hypoxia were mediated by inhibition of histamine, we introduced HA into tumor cells treated with cetirizine platinum complex 1 and assessed the levels of COX-2, HIF-1α, and VEGFA using Western blot. Fig.14The results showed that compared with cells treated with cetirizine tetravalent platinum complex 1, the expression of COX-2, HIF-1α and VEGFA in 4T1 tumor cells treated with a mixture of cetirizine tetravalent platinum complex 1 and HA (1-HA) was significantly increased (P<0.001), indicating that inflammation and hypoxia were aggravated. Subsequently, compared with the cetirizine tetravalent platinum complex 1 group, HUVEC angiogenesis in the 1-HA group was significantly increased (P<0.001) ( Fig.11 ). These trends were similar to those of CDDP-CTZ and CDDP-CTZ-HA mixtures. Our results suggest that the antiangiogenic properties of cetirizine platinum complex 1 are affected by histamine-mediated inflammatory and hypoxic microenvironment.
[0136] In conclusion, cetirizine tetravalent platinum complex 1 effectively inhibited tumor angiogenesis by inhibiting histamine-mediated inflammation and hypoxic TME, and inhibition of COX-2 / MMP-9 and HIF-1α / VEGFA signaling was the key to the anti-angiogenic effect.
[0137] 7. Activate immunity by inducing T cell activation and macrophage polarization
[0138] HA-HRH1 is an important player in regulating immune responses. At the same time, abnormal phosphorylation of PI3K / AKT / mTOR in the TME can greatly promote the immune escape of tumor cells through multiple signal transductions. The immune checkpoint PD-L1 is closely related to HA secretion and the PI3K pathway, and is involved in the exhaustion of T cells, leading to macrophage M2 polarization and promoting tumor progression. Therefore, inhibiting histamine and the PI3K / AKT / mTOR signal transduction network can effectively enhance anti-tumor immunity. In view of the anti-histamine and PI3K pathway inhibition properties of cetirizine tetravalent platinum complex 1, we tested the immunomodulatory properties of cetirizine tetravalent platinum complex 1 by Western Blot and immunohistochemistry.
[0139] The results are as follows Fig.15 As shown in the results, cetirizine tetravalent platinum complex 1 inhibited the expression of PD-L1 in tumor cells, and its expression level was significantly lower than that in the blank group and CDDP group (P < 0.001). Subsequently, in vivo tumor tissue immunohistochemistry also confirmed the inhibitory effect of compound 1 on PD-L1 (P < 0.001). Next, T cell immunity in tumor tissue was activated, and in the complex 1 treatment group, CD3 + and CD8 + The number of T cells increased by 8.7 times and 12.8 times compared with the blank group (P<0.001), and was also higher than that of the CDDP group (P<0.001). The results of macrophage staining showed that cetirizine tetravalent platinum complex 1 can effectively activate macrophage immunity and promote the polarization of macrophages from M2 to M1.+ The number of M1 macrophages increased (P<0.001), while the number of CD206+M2 macrophages decreased (P<0.001). In addition, the immune activation effect of cetirizine tetravalent platinum complex 1 was significantly better than that of CDDP group and CDDP-CTZ group.
[0140] It can be seen that cetirizine tetravalent platinum complex 1 can enhance CD3 by blocking the immune checkpoint PD-L1 + and CD8 + The T cell level can enhance T cell immunity and initiate macrophage polarization from M2 to M1 to enhance macrophage immunity. In summary, cetirizine tetravalent platinum complex 1 can reverse the immunosuppressive TME and enhance its anti-proliferative and anti-tumor metastasis properties.
[0141] 8. In vivo antitumor activity
[0142] To evaluate the antitumor effect of CTZ tetravalent platinum complex in vivo, we assessed the antitumor activity of cetirizine tetravalent platinum complex 1 in female BALB / c mice bearing 4T1 tumors, CDDP and the mixture CDDP-CTZ were used as positive control drugs, and the saline treatment group served as blank.
[0143] BALB / c female mice (18-20 g) were purchased from Shandong Pengyue Laboratory Animal Breeding Co., Ltd. All animals were fed in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.
[0144] After in vitro expansion of 4T1 cells, the cells were digested and collected, and the cells were washed three times with saline. The cells were resuspended in saline solution. Tumor cells were inoculated on the right back of female BALB / c mice at a density of 5×10 5 / mouse. On the third day after inoculation, the tumor was palpable. The mice were randomly divided into 4 groups, 6 mice in each group: normal saline group, cetirizine tetravalent platinum complex 1 group, CDDP group, CDDP-CTZ group, and the dosage was 2mg Pt / kg. The drug was administered on the 3rd, 6th, and 9th days, for a total of 3 times, by tail vein injection ( Fig.16 a). The changes in mouse tumor volume were recorded during the experiment to evaluate the tumor growth rate ( Fig.16 b); Record the changes in mouse body weight to evaluate drug toxicity ( Fig.16 f). On the 12th day, the mice were killed and their serum, tumor tissues, and organ tissues including heart, lung, liver, spleen, and kidney were collected. Tumor and visceral tissues were weighed ( Fig.16 c). Tissue samples were fixed with formalin and evaluated by hematoxylin and eosin (H&E) staining and immunohistochemical analysis ( Fig.16 g).
[0145] Fig.16 The results in bc and 16e showed that the candidate cetirizine tetravalent platinum complex 1 can effectively inhibit 4T1 tumors (323mm in vivo 3 ) growth, compared with the blank group (833mm 3 ) showed a tumor growth inhibition rate (TGI) of 74.4%, which was significantly better than the reference drug CDDP (529 mm 3 , TGI = 41.0%, P < 0.001) and CDDP-CTZ mixture (515 mm 3 , TGI=56.8%, P<0.001). Subsequently, H&E staining images of the tumor ( Fig.16 g) It was further confirmed that compared with CDDP and CDDP-CTZ, cetirizine tetravalent platinum complex 1 can induce more tumor cell apoptosis, causing severe degeneration, necrosis and nuclear dispersion. Uptake is considered to be a key factor affecting the anti-tumor effect of chemotherapeutic drugs. Therefore, we detected the uptake of drugs in tumors by AAS ( Fig.16 d). Similar to the uptake trend of the drug in tumor cells in vitro, the accumulation level of cetirizine tetravalent platinum complex 1 in vivo is also higher than that of the divalent platinum drug CDDP and CDDP-CTZ mixture, which is a key factor affecting the anti-tumor activity of the drug in vivo.
[0146] Systemic toxicity is an important factor affecting the future development and application prospects of drugs. Cetirizine tetravalent platinum complex 1 did not cause significant weight loss in mice at a dose of 2 mgPt / kg ( Fig.16 f), there was no difference compared with the blank group (P = ns); while CDDP and CDDP-CTZ mixture caused a significant decrease in body weight, which was significantly different from the blank group (P < 0.001). We further investigated the damage of drugs to internal organs by calculating the visceral index (ratio of visceral mass to body weight). Fig.17 The results showed that CDDP and CDDP-CTZ mixtures caused significant spleen inhibition (P<0.001), while compound 1 did not have this phenomenon, which confirmed that compound 1 was less toxic to the spleen than CDDP and CDDP-CTZ, which would further affect the immune response of mice. H&E staining cell morphology studies further proved that cetirizine tetravalent platinum complex 1 had low toxicity, and no obvious morphological changes were observed in the liver, spleen and kidney tissues of the cetirizine tetravalent platinum complex 1 treatment group ( Fig.18 ). In summary, cetirizine tetravalent platinum complex 1 has significant anti-tumor activity, its anti-tumor ability is stronger than cisplatin, and its toxicity is significantly lower than cisplatin.
[0147] 9. In vitro and in vivo metastasis inhibition experiments
[0148] Metastasis is the main cause of death in patients with malignant tumors, and about 90% of cancer patients die from tumor metastasis. The present invention investigates the in vivo and in vitro anti-tumor metastasis activity of the cetirizine tetravalent platinum lead compound 1.
[0149] Transwell assay: The assay was performed in a Transwell chamber containing micropores (8 μm pores). First, 4T1 cells (5 × 10 4 Cells) were resuspended in RPMI1640 (serum-free) medium and inoculated in the upper chamber, and 10% FBS-RPMI1640 medium with different compounds was added to the lower chamber. Secondly, the cells were incubated in a 37°C incubator containing 5% CO2 for 24 hours. Then, the cells were fixed with 4% paraformaldehyde for 20 minutes and stained with 0.1% crystal violet for 20 minutes. The non-migrated cells in the upper chamber were gently scraped off with a cotton swab. The migrating cells on the lower surface of the chamber were photographed in five random fields of view with an inverted microscope to investigate the anti-migration effect of the drug.
[0150] Scratch assay: 4T1 cells (8×10 5 ) were inoculated in a six-well cell culture plate and incubated in a 37°C incubator containing 5% CO2 for 12 hours. After the cell density reached 90%, scratch treatment was performed in each well. Then, the cells were treated with 1% FBS-RPMI1640 medium containing the compound, and the degree of healing of the scratch was recorded by taking photos at 0, 12 and 24 hours to investigate the anti-migration effect of the drug.
[0151] In vivo anti-metastasis experiment: BALB / c female mice (18-20 g) were used as experimental subjects. 4T1 cells (2×10 5 ) to establish a lung metastasis model. The mice were randomly divided into 3 groups (n=5): 1, CDDP and saline (Blank group) treatment. The drug was injected into the tail vein 3 times on the 3rd, 6th and 9th days after cell inoculation, with a dose of 2 mg Pt / kg. The mice were killed on the 12th day, and the lung tissues were dissected ( Fig.21 a). Then, after fixation with 4% formaldehyde solution for 24 hours, the lung metastatic nodules of each mouse were counted and the lung tissues were observed by H&E staining.
[0152] Fig.19 and 20 The results of Transwell and wound healing experiments in the experiment showed that compared with the blank group, cetirizine tetravalent platinum complex 1 could effectively inhibit the migration of tumor cells in vitro (P<0.001). In addition, the anti-metastatic ability of cetirizine tetravalent platinum complex 1 was significantly better than that of the reference drug CDDP (P<0.001) and the mixture CDDP-CTZ (P<0.001).
[0153] The lung is a major site of tumor metastasis. Fig.21 The activity of the lung metastasis model shown in bc indicates that the candidate drug cetirizine tetravalent platinum complex 1 also shows significant anti-metastatic activity in vivo. Compared with the blank group, the inhibition rate of cetirizine tetravalent platinum complex 1 on lung nodules was 85.6% (P < 0.001), which was significantly higher than CDDP (51.4%, P < 0.001). Subsequently, the H&E staining results of the tumor sections further showed that ( Fig.21 d), the tumor nodules in the group treated with cetirizine tetravalent platinum complex 1 were fewer and smaller. It can be seen that the candidate cetirizine tetravalent platinum complex 1 not only has good anti-proliferative activity, but also has strong anti-tumor metastasis activity, and has great development potential as an anti-metastatic drug.
[0154] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A derivative having a tetravalent platinum structure of cetirizine, the general formula of which is shown in (I): in, Selected from cisplatin or oxaliplatin; L is hydroxyl or 2. The derivative having a tetravalent platinum structure of cetirizine according to claim 1, characterized in that: The derivative is selected from:
3. The method for preparing the derivative having the tetravalent platinum structure of cetirizine according to any one of claims 1 to 2, characterized in that: The synthetic route of the derivative is as follows: in: When the molar ratio of compound II to cetirizine (CTZ) is 1:1.0-1.5, compound II and cetirizine CTZ undergo a coupling reaction to obtain an asymmetric monosubstituted cetirizine-modified tetravalent platinum compound, that is, L is a hydroxyl group; When the molar ratio of compound II to cetirizine CTZ is 1:2.0-5.0, compound II and cetirizine CTZ undergo a coupling reaction to obtain a symmetrical disubstituted cetirizine-modified tetravalent platinum compound, that is, L is 4. The method for preparing a derivative having a tetravalent platinum structure of cetirizine according to claim 3, characterized in that: The specific preparation steps of the synthetic route are: In an inert gas atmosphere, cetirizine CTZ, a condensing agent, and an organic base are dissolved in an anhydrous organic solvent for reaction, compound II is added, and the reaction is carried out in the dark, and then the target compound is separated by post-treatment; wherein, When the molar ratio of compound II, cetirizine CTZ, condensing agent and organic base is 1:1.0-1.5:1.0-1.5:1.0-1.5; the feeding relationship of compound II and organic solvent is that 10-100 ml of organic solvent is added for every 1 g of compound II, an asymmetric monosubstituted cetirizine-modified tetravalent platinum compound is obtained; When the feeding molar ratio of compound II, cetirizine CTZ, condensation agent and organic base is 1:2.0-5.0:2.0-5.0:2.0-5.0; the feeding relationship between compound II and organic solvent is that 10-100 ml of organic solvent is added for every 1 g of compound II, a symmetrical disubstituted cetirizine modified tetravalent platinum compound is obtained.
5. The method for preparing a derivative having a tetravalent platinum structure of cetirizine according to claim 4, characterized in that: The inert gas is nitrogen, helium or argon; the condensing agent is TBTU, HATU or EDCI; the organic base is triethylamine, N,N-diisopropylethylamine or 4-dimethylaminopyridine; and the organic solvent is DMF or DMSO.
6. A pharmaceutical composition, characterized in that: It comprises the derivative represented by the general formula (I) as described in claim 1 or 2, and its pharmaceutically acceptable excipients.
7. Use of the derivative according to claim 1 or 2 or the pharmaceutical composition according to claim 6 in the preparation of anti-tumor drugs.
8. The use according to claim 7, characterized in that: Specifically, it is used in the preparation of anti-tumor proliferation and anti-tumor metastasis drugs.
9. The use according to claim 8, characterized in that: The anti-tumor is against lung cancer, drug-resistant lung cancer, liver cancer or breast cancer; the anti-tumor proliferation is against proliferation of human lung adenocarcinoma, cisplatin-resistant human lung adenocarcinoma, human liver cancer or mouse breast cancer; the anti-tumor metastasis is against metastasis of mouse breast cancer cells.
10. A combined preparation comprising the derivative of general formula (I) as claimed in claim 1 or 2 or the pharmaceutical composition as claimed in claim 6, and an anti-tumor drug of the platinum type, paclitaxel type, fluorouracil type, gemcitabine type, vinca alkaloid type or antibody type.
Citation Information
Patent Citations
Platinum (II) compound with targeting effect as well as derivative, preparation method, pharmaceutical composition and application thereof
CN116178443A
Derivative with ciclopirox olamine tetravalent platinum structure and preparation method and application thereof
CN118084981A
